Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor-Like 1 (ORL-1) Partial Agonist, in Patients With Isolated Systolic Hypertension-Reference-Cited by-同舟云学术

Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor-Like 1 (ORL-1) Partial Agonist, in Patients With Isolated Systolic Hypertension

Published:2016-12-29 Issue:6 Volume:6 Page:584-591
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Kantola Ilkka¹,Scheinin Mika²,Gulbrandsen Trygve³,Meland Nils⁴,Smerud Knut T.⁴

Affiliation:

1. Division of Medicine; Turku University Hospital; Turku Finland

2. CRST Ltd; Itäinen Pitkäkatu Turku Finland

3. Serodus ASA; Gaustadalleen Oslo Norway

4. Smerud Medical Research International AS; Karenslyst alle Oslo Norway

Funder

Norges Forskningsråd

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.330/fullpdf

Reference10 articles.

1. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential;Lambert;Nat Rev Drug Discov,2008

2. Pharmacology of nociceptin and its receptor: a novel therapeutic target;Calo’;Br J Pharmacol.,2000

3. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications;Chiou;Curr Drug Targets,2007

4. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice;Rizzi;Br J Pharmacol.,2002

5. Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH∼2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity;Kapusta;J Pharmacol Exp Ther.,2005

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repurposing opportunities for chronic kidney disease;iScience;2024-06

2. Sex-stratified genome-wide association and transcriptome-wide Mendelian randomization studies reveal drug targets of heart failure;Cell Reports Medicine;2024-02

3. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics;Drugs;2023-05-20

4. OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects;Behavioural Pharmacology;2022-08-03

5. Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists;British Journal of Pharmacology;2021-12-12